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Abstract We demonstrate a novel inorganic-organic crystalline nanoconstruct, where gold atoms were
imbedded in the crystal lattices as defects of camptothecin nanocrystals, suggesting its potential use as
simultaneous agents for cancer therapy and bioimaging. The incorporation of gold, a potential computed
tomography (CT) contrast agent, in the nanocrystals of camptothecin was detected by transmission
electron microscope (TEM) and further quantified by energy dispersive X-ray spectrometry (EDS) and
inductively coupled plasma-optical emission spectrometers (ICP-OES). Due to gold's high attenuation
coefficient, only a relatively small amount needs to be present in order to create a good noise-to-contrast
ratio in CT imaging. The imbedded gold atoms and clusters are expected to share the same biological fate
as the camptothecin nanocrystals, reaching and accumulating in tumor site due to the enhanced
permeation and retention (EPR) effect.
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1. Introduction
The development of multimodal nanomedicine, which combines
the therapeutic and diagnostic capabilities, has tremendous poten-
tial to revolutionize the future of cancer therapy. By incorporating
bio-imaging agent molecules, the delivery of therapeutic agent can
be potentially monitored and traced in vivo. Over the past decade,
the application of fluorescent markers, both organic- and inor-
ganic-based material, has been vastly explored1,2. While organic
dyes may suffer from limitations, such as photobleaching, biode-
gradation, and narrow excitation/broad emission spectra, the lack
of biocompatibility and high toxicity hinders the utilization of the
inorganic markers3. In addition, fluorescence imaging is still
limited to in vivo studies due to low sensitivity and shallow
optical path. Current imaging modalities, including positron
emission tomography (PET), computed tomography (CT), mag-
netic resonance imaging (MRI), and ultrasound, can provide
anatomical patterns and basic information regarding tumor loca-
tion, size, and progression and are still the standard clinical
tools4,5.
Attributed to its availability, efficiency, and cost, X-ray based
CT is among the most convenient imaging/diagnostic tools in
hospitals today6,13. Iodinated aromatic molecules are the most
commonly contrast agent used in clinics and dominate the X-ray
contrast media markets7,8. Due to its rapid renal clearance,
however, approximately 100–200 mL of highly concentrated
iodinated contrast medium solution (ca. 600 mg/mL) are adminis-
tered intravenously to achieve adequate contrast8. Adverse reac-
tions caused by excessive amount of chemicals have also been
reported8–10. In the past few years, the feasibility of using gold
nanoparticles as a CT contrasting agent has been tested in vivo,
both through passive11,12 or active12,13 targeting. Within a CT
image, one can distinguish the difference between tissues based on
the degrees of the X-ray attenuation; more X-rays are attenuated in
denser tissues. The contrast of structure or fluid within the body
can be enhanced by utilizing contrast agent, where its attenuation
coefficient is determined by the atomic number and electron
density. Because gold's atomic number and electron density (79
and 19.32 g/cm3, respectively) are higher than iodine (53 and
4.9 g/cm3, respectively), gold gives a higher mass attenuation
coefficient. For instance, at 100 keV (a standard X-ray energy for
diagnostic imaging), gold and iodine have attenuation coefficient
of 5.16 and 1.94 cm2/g, respectively14; thus, gold provides about
2.7 times stronger contrast per unit weight than iodine. In addition,
the low toxicity and good biocompatibility15 make gold (clusters
and nanoparticles) an ideal contrast agent. More importantly,
regardless the shape of gold nanoparticles, the only important
parameter in CT imaging is the total amount of gold per unit
volume13. The utilization of gold as contrast agent in vivo was first
reported in 200612, and it is being continually explored.
In the past two decades, colloidal drug delivery systems
(CDDS), including liposomes16, solid lipid nanoparticles17, poly-
meric nanoparticles18, and micelles19, have been used to formulate
highly insoluble antic drugs. Despite the fact that these systems
have been extensively studied, various inherent limitations remain.
They generally have limited drug loading capacity20,21. Phospho-
lipid-based structures, such as liposomes, may also suffer from
drug leakage and instability during the preparation, storage, and
administration process that can compromise the therapeutic out-
comes22,23. As such, more physically stable and solvent-free
nanocrystals-based formulation may be used for delivering anti-
neoplastic drugs and reach the tumor site in the solid form.
Nanocrystals formulated from poorly soluble drugs may not
dissolve quickly24, providing a potential vehicle or carrier for a
contrast agent. This multimodal design may lead to cancer
theranostic systems, which can be passively targeted to tumor site
via enhanced permeation and retention (EPR) effect25. The
fundamental concept of such an integrated crystalline system lies
in physical inclusion of a bioimaging substance in the crystal
lattices as defects of a host drug compound; no chemical
conjugation is thereby needed. Herein, the purpose of this report
is to demonstrate successful incorporation of gold ions or atoms
and their clusters in the nanocrystals of a chemotherapeutic drug,
camptothecin (CPT). The idea of this novel hybrid nanocrystal was
inspired by the studies of “dyeing crystals”26, where organic dyes
are imbedded in organic crystals. To the best of our knowledge,
purported incorporation of an inorganic material into organic
nanocrystal lattices for biomedical applications has not been
previously reported.
CPT was selected as the model drug because it has a broad
spectrum of therapeutic activity against various cancer types27,28.
Similar to other chemotherapeutic agents, CPT has a low solubility
in water (ca. 1.2 μg/mL at 25 °C). It also has a well-established
clinical and been the focus of numerous drug delivery studies since
its discovery in 196629. Specifically, the antitumor activity of CPT
results from its ability to actively target and inhibit the DNA
enzyme topoisomerase I (TOP1). Unfortunately, the clinical
application of the drug remains greatly limited, largely due to its
inherent instability in solution as well as protein binding in the
plasma. The native, biologically active compound may undergo
hydrolysis and produce an inactive form (Fig. 1). The ring-open
reaction, which converts the lactone to carboxylate, occurs above
pH 7. Despite the chemical instability of the molecule, pure CPT
nanocrystals showed to accumulate in tumor and inflict the
antitumor effect, as demonstrated in our recent study30. In our
experiments reported here, preparation and storage of hybrid CPT
nanocrystals were conducted in pH 4-water to maintain its active
lactone form.
2. Materials and methods
2.1. Materials
Camptothecin (499%) was purchased from 21CECPharm (UK);
all other chemicals and solvents were obtained from Sigma (St.
Figure 1 The two forms of camptothecin (CPT).
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Louis, MO, USA) and Fisher Scientific (Pittsburgh, PA, USA).
200-mesh Lacey carbon grids were from Electron Microscopy
Sciences (Hatfield, PA, USA).
2.2. Preparation of hybrid nanocrystals
To produce hybrid CPT/gold nanocrystals, 40 mL of boiled pH
4 water (adjusted with 0.25 mol/L HCl) and 3 mL of 1 mmol/L
hydrogen tetrachloroaurate, HAuCl4, were added together in a
three-neck flask. The mixture was stirred at 500 rpm with a stirrer
shaft and under intense sonication (F20D, Fisher Scientific,
Pittsburgh, PA, USA). Next, 0.3 mL of 1% trisodium citrate
dehydrate aqueous solution was added to the flask. While the
gold salt solution was being reduced, 2 mL of 1 mg/mL CPT
dimethyl sulfoxide (DMSO) solution was added. The system
continued to be sonicated and stirred to promote crystal growth
and gold reduction. The solution changed its color from clear to
pinkish. To produce hybrid CPT/gold ions nanocrystals, the same
procedure was performed except for the addition of 0.3 mL of 1%
trisodium citrate dehydrate aqueous solution. As such, gold was
entrapped in the CPT nanocrystals as ions (chloroaurate). Because
of the absence of redox reaction, the solution and retentate
remained colorless.
Once hybrid nanocrystals formed, the crystals were harvested
by vacuum filtering with a 50-nm polycarbonate nuclepore filter.
With the vacuum filtration system still intact, approximately 5 to
10 mL of pH 4 water was added to rinse off any gold atoms or ions
that were not incorporated or attached to the nanocrystals. The
product harvested on the filter was then re-suspended in pH
4 water by sonicating the filter paper. For further removal of free
gold clusters or ions, the procedure of filtration, washing and re-
suspension by sonication was repeated three more times. Follow-
ing the final filtration process, the product collected on the filter
paper was re-suspended in 1 mL of pH 4 water and diluted with
aqua regia for gold analysis by inductively coupled plasma, or ICP
(Vista-Pro ICP-OES, Varian, Palo Alto, CA, USA). Filtrate from
each filtration process was also collected for mass balance
calculation. Only trace amount of CPT and gold were present in
the second and third filtrate; thus, only the first filtrate was
analyzed by ICP. Before mixing with the digestion solution,
filtrate was concentrated by boiling the water, leaving a total
volume of 5 mL.
2.3. Analysis of hybrid nanocrystals
The Varian Vista-Pro ICP-OES was utilized to quantify the
amount of the gold incorporated. 1 mL of either the concentrated
product or filtrate was dissolved with 1 mL of freshly mixed aqua
regia (1:3 mixture of concentrated nitric acid and hydrochloric
acid) and diluted with 3 mL of deionized water. Standard solutions
were prepared by using ICP standard for gold (Fisher Scientific,
Pittsburgh, PA, USA) diluted with aqua regia at concentrations of
0.010, 0.050, 0.1, 0.5, 1, 5, 10, and 50 ppm. Analysis was
performed at wavelength of 267 nm. Quantification of CPT was
conducted by high-pressure liquid chromatography (HPLC,
Waters Breeze, Milford, MA, USA) with UV detection (Waters
2487 dual λ absorbance detector) at 256 nm. A Waters' Symmetry
C18 5 μm column (150 mm × 4.6 mm) was used at 33 °C with a
mixture (36:64) of acetonitrile and 2% triethylamine aqueous
solution, adjusted to pH 5.5 by acetic acid, as the mobile phase
pumped at a rate of 0.5 mL/min (Waters 1525 binary pump).
2.4. Electron microscopy imaging and energy dispersive X-ray
spectroscopy (EDS)
SEM images were obtained using Hitachi SEM 4300 (Tokyo,
Japan) at an accelerating voltage of 3 kV. Prior to visualization,
samples were coated with conductive layers of gold palladium
(Au/Pd) for 1 min with current of 20 mA in a sputter coater,
resulting in approximately 15 nm thick coating. The coating helped
Figure 2 TEM (A) and STEM (B) images of CPT/gold hybrid nanocrystals without vigorous washing and filtering.
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to reduce sample charging. The freeze-dried hybrid nanocrystals
were imaged by using JEOL 2010F TEM (JEOL USA, Peabody,
MA, USA) equipped with an Oxford EDS detector. TEM was
operated at 200 keV. Scanning Transmission Electron Microscopy
(STEM) was performed at high angle conditions of approximately
50 mrad, using a 1.7 Å high resolution probe. EDS was performed
under STEM conditions using a 1 nm analytic probe. A small
amount of the freeze dried hybrid nanocrystals were rubbed on the
Lacey carbon grid and placed in the sample holder for imaging.
Samples obtained after one cycle of washing and re-suspension
was compared to that washed and re-suspended three times.
3. Results and discussion
Incorporation of gold in CPT nanocrystals was attempted in two
ways to retain gold atoms or gold ions. Both preparations were
conducted in a single step, eliminating typical multi-step chemical
treatment of conjugating bio-imaging agents31,32. To make hybrid
nanocrystals of CPT and gold atoms, chloroauric acid was reduced
concurrently when the nucleation of camptothecin nanocrystals
was triggered via the anti-solvent method. The redox reaction was
based on a simple route developed by McFarland et al.33, where
citrate aqueous solution was added to reduce the chloroauric acid.
It is believed that the reduced gold was integrated into CPT
nanocrystals as individual atoms and clusters. As the reduction
progressed, the solution changed from clear to pinkish. While the
reducing agent was introduced, a high concentration of dissolved
CPT in dimethyl sulfoxide (DMSO) was added to the aqueous
media of pH 4, resulting in nucleation and growth of CPT
nanocrystals. In the case of incorporating gold ions, citrate solution
was not added. Thus, without the reduction step, individual or
clusters of chloroauric acid are believed to be entrapped in the
crystal lattices of the CPT nanocrystals. At the end of each batch
process, product was filtered with 50-nm polycarbonate filter paper
and freeze-dried either with (Fig. 2) or without (Fig. 3) extra
washing and re-suspension step.
The hybrid camptothecin nanocrystals had morphology of
rectangular thin sheet, with the length ranged from approximately
300 nm to 1.5 µm (Fig. 2). The exact average size could not be
precisely determined by dynamic light scattering (DLS) because of
the nanocrystals' high aspect ratio. The TEM and STEM images
(Fig. 2) clearly showed that gold clusters were attached and
incorporated to the organic nanocrystals with high affinity, even
after vigorous washing and sonicating (Fig. 3). Visually, the
hybrid nanocrystals seem to be aggregated, possibly due to the
freeze drying process. The size of the imbedded gold atom clusters
was approximately 10 nm (Figs. 2 and 3), consistent with the size
reported by McFarland et al.33 EDS analysis of the gold clusters in
the CPT nanocrystals revealed that the expected characteristic
peaks of oxygen (O), carbon (C), gold (Au), and copper (Cu) were
present. The oxygen and carbon peaks were due to the drug, CPT,
and the copper peak was due to the TEM sample holder.
In the absence of reduction of chloroauric acid during the
nanocrystal preparation, individual or clusters of gold ions
(chloroaurate) were incorporated in the camptothecin nanocrystals
(Fig. 4A). The clusters of these ions were approximately 1.4 nm in
size (Fig. 4B and B*), and the individual gold ions seen as white
spots were approximately 2 Å in diameter (Fig. 4C and C*). The
white spots are believed to be individual gold ions incorporated as
crystal defects of the camptothecin nanocrystals. If these ions were
not imbedded in the crystals, they would have been washed off by
the sonication step. The gold ions were also shown to be more
homogenously distributed relative to that of the reduced gold
atoms/clusters (Figs. 2 and 3). EDS analyses showed peaks of both
gold and chlorine. Fast Fourier Transform (FFT) image processing
was utilized to get more a detailed and optimized structure image
of the hybrid camptothecin nanocrystal (Fig. 5). In this analysis, a
Fourier transform was applied to Fig. 5A producing the diffracto-
gram Fig. 5C. The diffraction spots were then filtered as in
Figure 3 TEM (A) and STEM (B) images of CPT/gold hybrid nanocrystals after vigorous washing and filtering. An EDS spectrum of the area
highlighted in (B) is shown in (C).
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Fig. 5D, and an inverse Fourier transform applied producing image
Fig. 5B. This brings out the CPT lattice planes giving a lattice
spacing of approximately 4 Å.
The percent entrapment of gold in the camptothecin nanocrys-
tals was quantified by inductively coupled plasma-optically emis-
sion spectrometry (ICP-OES)34. Relative to the amount of the
starting material, 8.11% and 1.31% of gold atoms and chloroauric
acid (Table 1), respectively, were present in the hybrid nanocrys-
tals. The reduction process allows neutral gold clusters to form
quickly and to be entrapped to the camptothecin nanocrystals. On
the other hand, chloroaurate incorporation may be relatively
limited due to its ionized state in the solution and the need to
bind a counter ion (most likely, proton) prior to the entrapment. As
such, more gold atoms were integrated in the CPT nanocrystals
(Table 1). Note that these nanocrystals were vigorously washed
under sonication and re-filtered for multiple times, so the majority
of quantified gold atoms or ions were imbedded as chemical
impurity as defects in the crystal structure. The same phenomenon
is observed routinely in the nature. Colored diamonds and
gemstones originated when impurities are trapped in the lattice
defects. Interestingly enough, in the case of colored diamond,
impurities (e.g., N) can still be introduced in the exceptionally
strong diamond's lattice. Because of the rapid nucleation and
growth, the CPT nanocrystals may have more crystal defects and
thus incorporate more gold atoms/ions and their clusters.
The percentage of gold integration in the CPT nanocrystals may
permit bioimaging. Because of the sensitivity of CT imaging and
the high attenuation coefficient of gold, a good contrast-to-noise
image can be obtained at gold concentration of 100 μg/mL12,35,
which is approximately a hundred times lower than the cytotoxi-
city of gold nanoparticles. It is important to note that even at its
low dosing, gold can exhibit longer blood retention (i.e., allowing
prolonged imaging time) due to its inherent physical property of
high molecular weight12. Nonetheless, it seems that our hybrid
nanocrystals provide a much less amount of gold in vivo. Given
the largest loading percentage of gold in the CPT nanocrystals,
3.47% (Table 1), there would be 10.4 μg of gold delivered to a
mouse (at a typical intravenous dosing level of 100 μL × 3 mg/mL
of CPT), which is an order of magnitude less than the reported
value for obtaining good CT imaging (assuming that the blood
volume of a mouse is 1.2 mL)12,35. Still, considering the additional
advantages of maximizing integrity and minimizing clearance of
gold established by its entrapment in nanocrystals, which have
been shown to accumulate in the tumor because of the leaky
vasculatures present inside tumorous tissues and underdeveloped
lymphatic drainage (i.e., the EPR effect), the local gold concentra-
tion may be higher enough for CT imaging of cancer. In fact, it is
reported that the vascular pore cutoff size (i.e., transvascular gaps)
in the majority of tumors are between 380 and 780 nm, and it can
go as high as between 1.2 and 2 μm in MCa IV, murine mammary
carcinoma36,37. Our recent study of pure CPT nanocrystals in a
mouse tumor model has supported the tumor targeting and
antitumor capability of the nanocrystals30. In addition, the hybrid
nanocrystals can be delivered without the need of using toxic
solubilizing agents, likely resulting in the maximum tolerated dose
(MTD) by five to ten folds relative to conventional delivery
Figure 4 STEM images of CPT/chloroaurate hybrid nanocrystals after vigorous washing and filtering. (A) Individual or clusters of gold ions
(chloroaurate) were incorporated in the camptothecin nanocrystals. (B) shows clusters of gold ions, and (C) shows individual gold ions. Particle
analysis results of the white dots in (B) and (C) are shown in (B*) and (C*), respectively.
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systems that are prepared with organic solvents, surfactants, or
complexing compounds (e.g., cyclodextrin)24. The feasibility of
hybrid camptothecin/gold nanocrystals as a cancer theranostic
system will of course need to be further tested in vivo. With this
proof-of-concept at hand, alternate route including irradiating the
imbedded gold (or other inorganic elements such as samarium) and
converting to its radioisotope198, Au, may be pursued for radio-
imaging modalities.
4. Conclusions
Herein, we have demonstrated that gold, an inorganic material, can
be incorporated in the nanocrystals of an organic compound,
camptothecin in two different forms, atom and ion. Specifically,
gold was imbedded as the defects in crystal lattices and the hybrid
constructs could withstand multiple cycles of vigorous washing,
filtering, and re-suspension (under sonication) to retain the guest
substance. Incorporation of individual gold ion, as small as 2 Å
was able to be imaged by TEM. The concept of integrating
inorganic materials into organic nanocrystals likely leads to
creation of novel theranostic systems for combating cancers.
While high attenuation inorganic materials, such as gold, can be
utilized as contrast imaging agents, inorganic radioisotopes can
also be integrated in a similar fashion in drug nanocrystals for
other types of bioimaging applications.
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